RXi is committed to being a collaborative partner in the pursuit to develop new and improved therapeutics with biotech, academia and large multi-national organizations. Our relationships allow us to build prospective pipelines as well as evaluate new technologies that augment our discovery and development initiatives. Some of our current collaborative partners are:
Biogazelle is a Ghent University spin-off founded in 2007 by Professor Jo Vandesompele and Dr. Jan Hellemans. It is focused on the development of RNA-targeted therapeutics and has proprietary knowledge to prioritize candidate therapeutic RNA targets in specific cancer types, building on years of expertise in exploring the human transcriptome. Therapeutic inhibition of candidate lncRNA targets are evaluated in high-throughput in vitro RNA perturbations and in preclinical animal models.
Being at the forefront of the genomics revolution, Biogazelle is convinced that unraveling the coding and non-coding regions of the genome will lead to RNA-targeted therapeutics and biomarkers for better healthcare.
Jade Therapeutics develops local ocular, polymer-based products designed to treat poorly-served ophthalmic indications. The Company’s proprietary, cross-linked, bio-erodible hydrogel technology (CMHA-S) has demonstrated a variety of unique and beneficial characteristics, whether employed alone as a corneal repair gel (JDE-003) and dry eye therapy (JDE-001) or as a sustained-release drug-delivery vehicle for proteins, siRNAs and small molecules. Jade opened an IDE for JDE-001 in 2015 and plans on clinical trials for both JDE-001 and 003 in 2016.
MirImmune is a biopharmaceutical company focused on the development of new and improved immunotherapies for cancer. Aiming to achieve long-term survival of cancer patients, they combine two leading approaches to cancer treatment: immune checkpoint inhibition and cell-based immunotherapies.
The National Alopecia Areata Foundation (NAAF) is widely regarded as the largest, most influential and most representative organization dedicated to improving the lives of individuals with alopecia areata: an autoimmune skin disease causing hair loss and, in many cases, emotional pain with a cumulative lifetime incidence of 2.1% which translates into 155 million people worldwide who have, had, or will develop alopecia areata at some point in their lives. As a 501(c)(3) non-profit, NAAF funds research to find a cure or acceptable treatment for alopecia areata and related diseases, supports those with the disease, and educates the public about alopecia areata. NAAF has been the driver of alopecia areata research for over 30 years and is dedicated to finding an effective treatment or cure for all those affected by the disease.
Thera is a biotechnology company dedicated to the discovery, development and commercialization of a new class of disease-modifying small molecules and RNA-based compounds for the treatment of neurologic disorders, initially focusing on Amyotrophic Lateral Sclerosis (ALS) and eventually expanding to traumatic brain injury (TBI), Alzheimer's disease (AD) and multiple sclerosis (MS).